연말 거래 업데이트
Arecor Therapeutics plc
("아코르" 또는 "그룹")
연말 거래 업데이트
- Patient enrolment complete in AT278 clinical trial and on track for key data readout in 1H 2024
- First commercial launch of product incorporating Arestat?, AT220, triggering milestone payment and now generating royalties
- New revenue-generating technology partnership agreements signed
- Total Income of £5.6 million (2022: £3.5 million) including grant income
- Total Group revenue of £4.6 million (2022: £2.4 million) representing c.90% growth
- Tetris Pharma product sales increased to £2.9 million (2022: £1.0 million) with a focus on the commercial roll-out of Ogluo®
- Cash and cash equivalents balance of £6.8 million, ahead of market expectations
영국 케임브리지, 1년 2024월 XNUMX일: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, provides a business update and announces that its audited final results for the 12 months ended 31 December 2023 will be issued during the week commencing 22 April 2024.
Arecor의 CEO인 Sarah Howell은 다음과 같이 말했습니다. "With a first commercial product incorporating Arestat? launched in late 2023 and now generating royalties, license milestones triggered on partnered products, a stream of new pharma technology partnerships and continued momentum with our diabetes portfolio clinical development, we continue to realise the potential of our Arestat? platform and, in doing so, are building a significant biopharmaceutical company. We are encouraged by the continued success of the Tetris Pharma roll-out of Ogluo® across the UK and Europe, which is reflected in strong sales performance as awareness and access to this key diabetes product increases. Looking forward, with further partnerships anticipated from our in-house proprietary specialty hospital portfolio, in addition to key Phase I clinical data for AT278 expected in 1H 2024, we look forward to continued growth and value creation for 2024."
Trading for the full year ended 31 December 2023
The strong commercial performance across the Group is reflected in the increased revenue for the full year of £4.6 million or c. 90% growth compared to £2.4 million recognised in the prior year. Total Income of £5.6 million (2022: £3.5 million) included grant income from the Innovate UK 2021 award. The Group closed its financial year with cash and cash equivalents of £6.8 million (2022: £12.8 million).
Revenue, total income, closing cash and cash equivalents balances are unaudited, with the Group's audited results to be issued during the week commencing 22 April 2024.
Licensed programmes - validating the value of the Arestat? platform to patients and growing a diversified revenue stream
Commercialisation by Arecor's partner of the first product incorporating Arestat? technology, AT220, was a significant milestone for the Group, further demonstrating the strength of its technology and its value to partners and ultimately patients. The first commercial sale in November triggered a license milestone payment and Arecor is now receiving royalties on product sales with initial royalties for the short period post launch included in 2023 revenues.
In addition to AT220, Arecor has two further partnered programmes under license - Hikma's development of ready-to-use injectable medicine AT307, and Inhibrx's development of alpha-1 antitrypsin deficiency therapy AT292 (INBRX-101), which continue to advance well under our partners' control and have both generated license milestone payments to Arecor within FY 2023.
Last month, Inhibrx and Sanofi announced that the companies have entered into a definitive agreement under which Sanofi will acquire all the assets and liabilities associated with INBRX-101. That announcement is a further endorsement of the Group's Arestat? platform and highlights both the value of this novel therapy for patients and its future commercial potential. The Group believes that Sanofi is well placed to complete the late-stage development of this novel medicine and, ultimately, bring it to patients in need.
In December, the Group announced a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute oncology product from Arecor's proprietary Specialty Hospital pipeline. The agreement involves further co-development and regulatory work which is now underway. The agreement includes an option for the partner to exercise a license to further develop and commercialise the product, with Arecor eligible to receive potential developmental milestones.
Technology partnerships - new revenue-generating collaborations
Our portfolio of technology partnerships with leading pharmaceutical and biotechnology companies, to enhance their proprietary products across a range of indications and stages of development, continues with five new agreements signed in 2023 and earlier this year. These continue to validate the strength and the need for the Arestat? technology platform, provide near term revenue generation and also significant upside recurring revenue potential from future licensing.
In November, the Group signed a further collaboration with an existing partner, Lilly, to develop a novel liquid formulation of one of Lilly's key products with enhanced properties. That was followed last month with the expansion of an ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world's largest chemicals marketing and pharmaceuticals companies, to develop a differentiated, ready-to-use liquid formulation of the company's product, AT351. In both collaborations, the Group's partners are funding the development work with options to acquire the rights to the new proprietary formulations and associated intellectual property under Arecor's technology licensing model. Both illustrate partner companies' confidence in the Group's expertise and its value as a partner of choice in the development of enhanced safe, efficacious and more convenient treatments that improve patient outcomes.
Further technology partnerships, the out-licensing of programmes from those partnerships, together with new licenses from the Group's proprietary pipeline, are anticipated to continue driving revenue growth in 2024.
Diabetes - creating a disrupter insulin
Diabetes has reached pandemic levels, with approximately 537 million adults living with diabetes worldwide. There are still significant unmet needs in diabetes care and the Group is focussed on developing much faster acting and more concentrated, rapid acting insulins, to improve treatment options and outcomes for this growing patient population within the existing $6.4 billion meal-time insulin market. The Group's Phase I clinical study of ultra-concentrated, ultra-rapid acting insulin candidate AT278 in the type 2 diabetes population, has completed patient enrolment and is on track to deliver results in 1H 2024. AT278 has the potential to be a critical enabler in the development of next generation miniaturised and longer wear insulin delivery systems, which are a significant area of focus for the major insulin device companies today.
Tetris Pharma - continued success of Ogluo® roll-out
The Group's specialty pharmaceutical business, Tetris Pharma, continues to build sales momentum through the commercial roll-out of its ready-to-use glucagon auto-injector pen for severe hypoglycaemia, Ogluo®. The increase in Tetris Pharma product sales to £2.9 million (2022: £1.0 million) was driven by Ogluo®, which now represents the majority of product sales. The appointment last month of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of Tetris Pharma, is an important catalyst to continue to drive Tetris Pharma revenue.
본 발표에는 보유 목적에 따른 내부 정보가 포함되어 있습니다. UK EU 시장 남용 규정(EU) 596/2014 버전("UK 망치다").
-ENDS-
자세한 내용은 문의하시기 바랍니다 :
Arecor Therapeutics plc | www.arecor.com |
CEO 사라 하웰 박사 | 전화 : + 44 (0) 1223 426060 이메일 : [이메일 보호] |
Susan Lowther, 최고 재무 책임자 | 전화 : + 44 (0) 1223 426060 이메일 : [이메일 보호] |
| |
Panmure Gordon (영국) 제한 (노마드와 Broker) | |
프레디 크로슬리, 엠마 얼(기업 금융) Rupert Dearden(기업 중개) | 전화 : + 44 (0) 20 7886 2500
|
WG 파트너스 LLP (금융 설계사) | |
나이젤 반스, 사티시 나다라자 데이비드 윌슨, 클라에스 스팽 | 전화 : + 44 (0) 203 705 9321 |
ICR 콘실리움 | |
크리스 가드너, 데이비드 데일리, 린지 네빌 | 전화 : + 44 (0) 20 3709 5700 이메일 : [이메일 보호] |
|
편집자 주
아레코 소개
Arecor Therapeutics plc는 혁신적인 의약품을 시장에 출시하여 환자 치료를 혁신하는 전 세계적으로 초점을 맞춘 바이오제약 그룹입니다. 기존 치료제의 개선을 통해 신청하여 당사의 혁신적인 독점 제형 기술 플랫폼, Arestat?, 우리는 당뇨병 및 기타 적응증에 대한 독점 제품의 내부 포트폴리오를 개발할 뿐만 아니라 주요 제약 및 생명 공학 회사와 협력하여 치료제의 향상된 제형을 제공합니다. 아레스타트? 플랫폼은 광범위한 특허 포트폴리오의 지원을 받습니다.. 자세한 내용은 당사 웹 사이트를 참조하십시오. www.arecor.com
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.